Cargando…

Minimal breast cancer: evaluation of histology and biological marker expression

Ninety-eight minimal breast cancers (MBCs) diagnosed between 1975 and 1990, and all originally considered to be invasive were found, on review, to form three groups: (a) 28 predominantly invasive carcinomas ≤10 mm (‘predominant invasive’); (b) 48 predominantly ductal carcinoma in situ (DCIS) lesions...

Descripción completa

Detalles Bibliográficos
Autores principales: Dublin, E A, Millis, R R, Smith, P, Bobrow, L G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363109/
https://www.ncbi.nlm.nih.gov/pubmed/10408407
http://dx.doi.org/10.1038/sj.bjc.6690570
_version_ 1782153622561226752
author Dublin, E A
Millis, R R
Smith, P
Bobrow, L G
author_facet Dublin, E A
Millis, R R
Smith, P
Bobrow, L G
author_sort Dublin, E A
collection PubMed
description Ninety-eight minimal breast cancers (MBCs) diagnosed between 1975 and 1990, and all originally considered to be invasive were found, on review, to form three groups: (a) 28 predominantly invasive carcinomas ≤10 mm (‘predominant invasive’); (b) 48 predominantly ductal carcinoma in situ (DCIS) lesions with definite foci of invasion each ≤10 mm (‘predominant DCIS’); and (c) 22 DCIS without evidence of invasion (‘pure DCIS’). Tumour histology and immunohistochemical expression of Ki-67, c-erbB2, p53, oestrogen receptor (ER), progesterone receptor (PR), and Bcl-2 were compared. The major finding was the contrasting features in the two invasive groups, with significant differences in their extent of invasion (P < 0.0001), tumour grade (P = 0.03), DCIS type (P = 0.008) and in marker expression. In the predominant invasive group, the infiltrative component was usually greater than 5 mm, low-grade and associated with well-differentiated DCIS. Expression of Ki-67, c-erbB2 and p53 was generally low, and that of ER, PR and Bcl-2 high. The predominant DCIS group in contrast had a much smaller, commonly high-grade, invasive component, usually with poorly differentiated DCIS and the reverse pattern of marker expression. Although not significant, survival of patients in the predominant invasive group was slightly better. These findings suggest that invasive MBCs should perhaps be treated as separate entities, in order to aid more appropriate selection of treatment. © 1999 Cancer Research Campaign
format Text
id pubmed-2363109
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23631092009-09-10 Minimal breast cancer: evaluation of histology and biological marker expression Dublin, E A Millis, R R Smith, P Bobrow, L G Br J Cancer Regular Article Ninety-eight minimal breast cancers (MBCs) diagnosed between 1975 and 1990, and all originally considered to be invasive were found, on review, to form three groups: (a) 28 predominantly invasive carcinomas ≤10 mm (‘predominant invasive’); (b) 48 predominantly ductal carcinoma in situ (DCIS) lesions with definite foci of invasion each ≤10 mm (‘predominant DCIS’); and (c) 22 DCIS without evidence of invasion (‘pure DCIS’). Tumour histology and immunohistochemical expression of Ki-67, c-erbB2, p53, oestrogen receptor (ER), progesterone receptor (PR), and Bcl-2 were compared. The major finding was the contrasting features in the two invasive groups, with significant differences in their extent of invasion (P < 0.0001), tumour grade (P = 0.03), DCIS type (P = 0.008) and in marker expression. In the predominant invasive group, the infiltrative component was usually greater than 5 mm, low-grade and associated with well-differentiated DCIS. Expression of Ki-67, c-erbB2 and p53 was generally low, and that of ER, PR and Bcl-2 high. The predominant DCIS group in contrast had a much smaller, commonly high-grade, invasive component, usually with poorly differentiated DCIS and the reverse pattern of marker expression. Although not significant, survival of patients in the predominant invasive group was slightly better. These findings suggest that invasive MBCs should perhaps be treated as separate entities, in order to aid more appropriate selection of treatment. © 1999 Cancer Research Campaign Nature Publishing Group 1999-07 /pmc/articles/PMC2363109/ /pubmed/10408407 http://dx.doi.org/10.1038/sj.bjc.6690570 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Dublin, E A
Millis, R R
Smith, P
Bobrow, L G
Minimal breast cancer: evaluation of histology and biological marker expression
title Minimal breast cancer: evaluation of histology and biological marker expression
title_full Minimal breast cancer: evaluation of histology and biological marker expression
title_fullStr Minimal breast cancer: evaluation of histology and biological marker expression
title_full_unstemmed Minimal breast cancer: evaluation of histology and biological marker expression
title_short Minimal breast cancer: evaluation of histology and biological marker expression
title_sort minimal breast cancer: evaluation of histology and biological marker expression
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363109/
https://www.ncbi.nlm.nih.gov/pubmed/10408407
http://dx.doi.org/10.1038/sj.bjc.6690570
work_keys_str_mv AT dublinea minimalbreastcancerevaluationofhistologyandbiologicalmarkerexpression
AT millisrr minimalbreastcancerevaluationofhistologyandbiologicalmarkerexpression
AT smithp minimalbreastcancerevaluationofhistologyandbiologicalmarkerexpression
AT bobrowlg minimalbreastcancerevaluationofhistologyandbiologicalmarkerexpression